» Articles » PMID: 17302980

An Adenovirus Prime/plasmid Boost Strategy for Induction of Equipotent Immune Responses to Two Dengue Virus Serotypes

Overview
Journal BMC Biotechnol
Publisher Biomed Central
Specialty Biotechnology
Date 2007 Feb 17
PMID 17302980
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dengue is a public health problem of global significance for which there is neither an effective antiviral therapy nor a preventive vaccine. It is a mosquito-borne viral disease, caused by dengue (DEN) viruses, which are members of the Flaviviridae family. There are four closely related serotypes, DEN-1, DEN-2, DEN-3 and DEN-4, each of which is capable of causing disease. As immunity to any one serotype can potentially sensitize an individual to severe disease during exposure to a heterologous serotype, the general consensus is that an effective vaccine should be tetravalent, that is, it must be capable of affording protection against all four serotypes. The current strategy of creating tetravalent vaccine formulations by mixing together four monovalent live attenuated vaccine viruses has revealed the phenomenon of viral interference leading to the manifestation of immune responses biased towards a single serotype.

Results: This work stems from the emergence of (i) the DEN virus envelope (E) domain III (EDIII) as the most important region of the molecule from a vaccine perspective and (ii) the adenovirus (Ad) as a promising vaccine vector platform. We describe the construction of a recombinant, replication-defective Ad (rAd) vector encoding a chimeric antigen made of in-frame linked EDIIIs of DEN virus serotypes 2 and 4. Using this rAd vector, in conjunction with a plasmid vector encoding the same chimeric bivalent antigen, in a prime-boost strategy, we show that it is possible to elicit equipotent neutralizing and T cell responses specific to both DEN serotypes 2 and 4.

Conclusion: Our data support the hypothesis that a DEN vaccine targeting more than one serotype may be based on a single DNA-based vector to circumvent viral interference. This work lays the foundation for developing a single Ad vector encoding EDIIIs of all four DEN serotypes to evoke a balanced immune response against each one of them. Thus, this work has implications for the development of safe and effective tetravalent dengue vaccines.

Citing Articles

Approaches of dengue control: vaccine strategies and future aspects.

Akter R, Tasneem F, Das S, Soma M, Georgakopoulos-Soares I, Juthi R Front Immunol. 2024; 15:1362780.

PMID: 38487527 PMC: 10937410. DOI: 10.3389/fimmu.2024.1362780.


Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses.

Shoushtari M, Roohvand F, Salehi-Vaziri M, Arashkia A, Bakhshi H, Azadmanesh K Hum Vaccin Immunother. 2022; 18(5):2079323.

PMID: 35714271 PMC: 9481145. DOI: 10.1080/21645515.2022.2079323.


Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?.

Alves A, Costa S, Pinto P Front Med Technol. 2022; 3:640964.

PMID: 35047911 PMC: 8757892. DOI: 10.3389/fmedt.2021.640964.


A Review on Dengue Vaccine Development.

Deng S, Yang X, Wei Y, Chen J, Wang X, Peng H Vaccines (Basel). 2020; 8(1).

PMID: 32024238 PMC: 7159032. DOI: 10.3390/vaccines8010063.


Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?.

Valdes I, Lazo L, Hermida L, Guillen G, Gil L Front Immunol. 2019; 10:1956.

PMID: 31507591 PMC: 6718459. DOI: 10.3389/fimmu.2019.01956.


References
1.
Mongkolsapaya J, Dejnirattisai W, Xu X, Vasanawathana S, Tangthawornchaikul N, Chairunsri A . Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9(7):921-7. DOI: 10.1038/nm887. View

2.
Khanam S, Khanna N, Swaminathan S . Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine. 2006; 24(42-43):6513-25. DOI: 10.1016/j.vaccine.2006.06.031. View

3.
Hung J, Hsieh M, Young M, Kao C, King C, Chang W . An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol. 2003; 78(1):378-88. PMC: 303388. DOI: 10.1128/jvi.78.1.378-388.2004. View

4.
Jaiswal S, Khanna N, Swaminathan S . High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr Purif. 2003; 33(1):80-91. DOI: 10.1016/j.pep.2003.09.009. View

5.
Kanesa-thasan N, Edelman R, Tacket C, Wasserman S, Vaughn D, Coster T . Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg. 2004; 69(6 Suppl):17-23. DOI: 10.4269/ajtmh.2003.69.17. View